Peptides DB
Research-centric peptide and protocol reference hub
Study 1 of 20Dulaglutide literatureFuture science OA · Case report2026

Severe numbness of the mouth and tongue induced by piperacillin/tazobactam: a rare case report.

Clinicians should be aware that severe adverse reactions to piperacillin/tazobactam can occur, even shortly after administration, and should monitor patients closely.

Read at Future science OAAdd to compare

Where it sits

this study against the rest of the dulaglutide corpus
2
Preclinical
11
Observational · this one
0
Open-label
3
Randomised
4
Reviews

Summary and findings

This case report describes a 58-year-old man who experienced severe oral and tongue numbness, dyspnea, and pruritus approximately 4 minutes after receiving intravenous piperacillin/tazobactam. The adverse reaction was identified as a previously unreported severe adverse drug reaction. No specific dose information was provided in the abstract.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.n=12026

Abstract

The authors’ words, as Future science OA supplied them

<h4>Background</h4>Severe oral and tongue numbness induced by piperacillin/tazobactam is extremely rare.<h4>Results</h4>A 58-year-old man with bacterial pneumonia developed oral and tongue numbness, dyspnea, and pruritus approximately 4 minutes after intravenous infusion of piperacillin/tazobactam. Based on adverse drug reaction causality assessment, this event was identified as a previously unreported severe adverse drug reaction.<h4>Discussion</h4>This case suggests that during clinical use of piperacillin/tazobactam, clinicians should remain vigilant for rare but severe adverse drug reactions even when skin testing is negative, and strengthen medication monitoring to ensure medication safety.

Background

This paper addresses the rare occurrence of severe oral and tongue numbness as an adverse reaction to piperacillin/tazobactam. While adverse drug reactions are known to occur with various medications, this specific reaction appears to be previously unreported. Understanding such rare reactions is critical for improving medication safety and monitoring practices in clinical settings.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

The findings highlight the importance of vigilance in monitoring for rare adverse drug reactions, even when prior testing does not indicate sensitivity. However, due to the nature of a single case report, the findings may not be broadly applicable or clinically significant across larger populations.

Key findings

  • Severe oral and tongue numbness occurred 4 minutes after intravenous infusion of piperacillin/tazobactam.
  • The patient was a 58-year-old man with bacterial pneumonia.
  • The adverse reaction was classified as a previously unreported severe adverse drug reaction.

Limitations

  • Single case report limits generalizability.
  • No specific dose or duration of treatment reported.
  • Lack of larger sample size to support findings.
  • No follow-up data provided.

Elsewhere in the Dulaglutide corpus

BImpact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.Digestive diseases and sciences · 2026 · 8.9% chronic diarrhea vs 10.6% in non-GLP-1 group at 90 days, p<0.001.HumanBPrescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.Clinical pharmacology and therapeutics · 2024 · n=2033 · GLP-1RA initiation inversely associated with antidepressants (aSR: 0.85; 95% CI: 0.76-0.94)HumanAEfficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).Diabetes, obesity & metabolism · 2026 · n=573 · ETD for HbA1c reduction: -0.74%; CI95: -0.90, -0.59HumanBProjecting the Long-Term Cost-Effectiveness of Once-Weekly Insulin Icodec Versus Once-Daily Basal Insulin Analogs in Italy Using the Prime T2D Model.Diabetes, obesity & metabolism · 2026 · 0.16 QALYs gained with icodec versus glargine U100 and degludec.BEfficacy and safety of SGLT2 inhibitors in elderly patients with type 2 diabetes.Annals of medicine · 2026 · n=9915 · HR 0.69 for 30% eGFR decline, 95% CI 0.59-0.80, p<0.001HumanDComparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trialsbiorxiv-preprint · 2026 · −0.25% HbA1c mean difference vs dulaglutide, 95% CI −0.38 to −0.12, p=0.0002review